---
title: 'First-line avelumab treatment in patients with metastatic Merkel cell carcinoma:
  4-year follow-up from part B of the JAVELIN Merkel 200 study'
date: '2024-05-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38744102/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240515180808&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Avelumab first-line monotherapy in patients with mMCC resulted
  in meaningful long-term OS, which compared favorably with historical studies of
  first-line chemotherapy. These results further support the role of avelumab as a
  standard of care for patients with ...'
disable_comments: true
---
CONCLUSIONS: Avelumab first-line monotherapy in patients with mMCC resulted in meaningful long-term OS, which compared favorably with historical studies of first-line chemotherapy. These results further support the role of avelumab as a standard of care for patients with ...